The Food and Drug Administration (FDA) has revised the draft guidance, “Rare Diseases: Common Issues in Drug Development Guidance for Industry”. The original draft guidance was issued August 2015. The revised draft guidance was published in the Federal Register February 1, 2019. Our previous blog mentioned that although it was available for public review January 16, there was a delay in publication and comment availability.
Rare diseases are frequently serious and life-threatening. The Orphan Drug Act (ODA) allows for incentives for sponsors to develop drugs or biologics for rare diseases. The drug or biologic must meet the criteria in 21 CFR 316.20 and 316.21 to be considered for orphan status. A new, streamlined process to increase efficiency and reduce burden with the FDA has been implemented as part of the FDA’s Orphan Drug Modernization Plan. The goal is to respond to orphan status requests within 90 days. This draft guidance will be released to aid sponsors in “conducting more efficient and successful drug development programs” for rare diseases.
The revised draft includes:
Updates to the “Natural History Studies” section.
Additional information on validation of biomarkers for surrogate endpoints.
Additional information about external, historical controls and early randomization.
Adding a safety section.
More information and clarification about manufacturing process and drug substance changes.
Adding an “Additional Considerations” section to address:
participation of patients, caretakers, and advocates,
consideration of pediatric issues,
and interactions with FDA.
The draft guidance is designed to address challenges to developing drugs and biologics for rare diseases where there are less data, knowledge, and experience. Click here to be taken to the FDA website to provide comments by April 2, 2019.
- The Clinical Pathways Team
Enjoy this blog? Please like, comment, and share with your contacts.